Mologen AG
Records under this name other than the patents Mologen AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,017,591 | Substituted, Non-Coding Nucleic Acid Molecule for Therapeutic and Prophylactic Stimulation of the Immune System in Humans and Higher Animals Formerly held In force · High confidence | In force | High confidence | |
| US 9,499,815 | Multimer for Immunostimulation Formerly held In force · High confidence | In force | High confidence | |
| US 10,487,333 | Combination Comprising Immunostimulatory Oligonucleotides Formerly held In force · High confidence | In force | High confidence | |
| US 11,583,581 | Methods of Treating a Latent HIV-1 Infection Using Non-Coding Deoxyribonucleic Acids Formerly held In force · High confidence | In force | High confidence | |
| US 10,006,032 | Predictive Biomarker for Cancer Therapy Formerly held Lapsed on the fee record Ended Jun 26, 2026 · High confidence | Lapsed on the fee record | Ended Jun 26, 2026 | High confidence |
| US 7,635,468 | Allogeneic Tumor Therapeutic Agent, a Vaccine Using Allogeneic Tumor Cells for the Therapeutic Treatment of Tumor Diseases, and a Method for the Making of Such a Vaccine, and Transfected Human Tumor Cells for Use as a Vaccine Formerly held Term ended Term ended Dec 30, 2024 · High confidence | Term ended | Term ended Dec 30, 2024 | High confidence |
| US 9,345,754 | Allogeneic Tumor Therapeutic Agent, a Vaccine Using Allogeneic Tumor Cells for the Therapeutic Treatment of Tumor Diseases, and a Method for the Making of Such a Vaccine, and Transfected Human Tumor Cells for Use as a Vaccine Lapsed on the fee record Ended May 24, 2024 · Medium confidence | Lapsed on the fee record | Ended May 24, 2024 | Medium confidence |
| US 9,212,366 | Immune Modulating Oligonucleotides in Connection with Chemotherapeutic Measures Formerly held Lapsed on the fee record Ended Dec 15, 2023 · High confidence | Lapsed on the fee record | Ended Dec 15, 2023 | High confidence |
| US 10,280,424 | Covalently closed non-coding immunomodulatory DNA construct Lapsed on the fee record Ended May 7, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 7, 2023 | From the USPTO record |
| US 7,795,406 | Agent for treating leishmania infections Lapsed on the fee record Ended Sep 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 14, 2022 | From the USPTO record |